News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|July 12, 2024

Evaluating Value of BTK Inhibitors in CLL Treatment

Author(s)Ryan Haumschild, PharmD, MS, MBA, Roy Beveridge, MD, Brian T. Hill, MD, PhD

Experts evaluate the value of BTK inhibitors in CLL treatment.

Episodes in this series

A panel of 4 experts on CLL

EP. 1 Recent Trends and Innovations in the Management of CLL

A panel of 4 experts on CLL

EP. 2 CLL Treatment Landscape: Overview of BTK Inhibitors

A panel of 4 experts on CLL

EP. 3 Evaluating Value of BTK Inhibitors in CLL Treatment

A panel of 4 experts on CLL

EP. 4 Factors Influencing Choice of Second-Generation BTKi Monotherapy

A panel of 4 experts on CLL

EP. 5 Empowering Patients: Key Considerations for BTK Inhibitor Adherence

A panel of 4 experts on CLL

EP. 6 Optimizing Therapy Sequencing in CLL

A panel of 4 experts on CLL

EP. 7 Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection

A panel of 4 experts on CLL

EP. 8 Decision-Making in CLL: The Role of Real-World Evidence

A panel of 4 experts on CLL

EP. 9 Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment

A panel of 4 experts on CLL

EP. 10 Financial Challenges of BTK Inhibitor Therapy in CLL: Impact on Access and Utilization

A panel of 4 experts on CLL

EP. 11 Navigating Access Challenges in CLL Treatment: Strategies for Overcoming Barriers 

A panel of 4 experts on CLL

EP. 12 The Inflation Reduction Act: Implications for Patient Access in CL

A panel of 4 experts on CLL

EP. 13 Patient Access Advocacy for BTK Inhibitors

A panel of 4 experts on CLL

EP. 14 Future Directions of BTK Inhibitors in Leukemia and Lymphoma

Video content above is prompted by the following question(s):

How are payers evaluating the value of BTK inhibitors in the evolving treatment landscape of CLL?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Ultimately, the authors said most patients will have more than one viable treatment option for first-line therapy, meaning that clinicians will need to rely on careful, informed discussions with patients. | Image credit: Eleni - stock.adobe.com

Novel CLL Therapies Prompt New Treatment Considerations

ByJared Kaltwasser

January 24th 2026

To confirm that the 2 epitypes were not unique to the initial dataset, the researchers validated their findings in 2 independent population-based cohorts. | Image credit: keetazalay - stock.adobe.com

Study Identifies 2 Distinct Epigenetic Subtypes Within Aggressive CLL

ByAJMC Contributor

January 21st 2026

CLL image | Image Credit: © Saiful52-stock.adobe.com

Limited Survival in CLL With CNS Richter Transformation

ByMaggie L. Shaw

January 16th 2026

Ira Zackon, MD | Image: NYOH

Evolving Treatment Paradigms for Hematologic Malignancies in Community Oncology Settings

ByPearl Steinzor

January 11th 2026

Dr David Kuter

Rilzabrutinib Offers a New, Well-Tolerated Option for Patients With ITP: David Kuter, MD, DPhil

ByBrooke McCormick,David Kuter, MD, DPhil

January 5th 2026

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

Trending on AJMC

CRC Becomes Leading Cause of Cancer-Related Death in Younger Adults, Highlighting Prevention Gaps

Unexplained Pauses Hit Nearly Half of Monthly-Updated CDC Databases, Raising Transparency Concerns

Novel CLL Therapies Prompt New Treatment Considerations

5 Ongoing Phase 3 Trials in Hematologic Malignancies

ACE Inhibitors Linked to Reduced Mortality in Patients with Idiopathic Pulmonary Fibrosis

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.